Carloni Riccardo, Rizzo Alessandro, Ricci Angela Dalia, Federico Alessandro Di, De Luca Raffaele, Guven Deniz Can, Yalcin Suayib, Brandi Giovanni
Department of Specialized, Experimental and Diagnostic Medicine, University of Bologna, Via Giuseppe Massarenti, 9, Bologna 40138, Italy; Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni, 15, Bologna 40138, Italy.
Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, Bari 70124, Italy.
Transl Oncol. 2022 Nov;25:101514. doi: 10.1016/j.tranon.2022.101514. Epub 2022 Aug 14.
Systemic treatments (e.g., chemotherapy and targeted therapies) have limited efficacy for patients with locally advanced - unresectable - and metastatic cholangiocarcinoma (CCA), with an overall survival of less than a year. Tumor microenvironment (TME) represents the ecosystem surrounding the tumor which comprises immune cells, fibroblasts, endothelial cells, and a wide range of soluble factors. CCA TME is characterized by an abundant desmoplastic stroma, exhibits a high heterogeneity and it plays a central role in cancer onset and progression. There is growing evidence suggesting that it is possible to target TME in association with other treatment modalities, such as cytotoxic chemotherapy or targeted therapies, paving the way to possible combination strategies with a synergistic effect. Herein, we describe the components of CCA TME - such as cancer-associated fibroblasts and other cells of pivotal importance - with their most relevant interactions, focusing on the preclinical rationale for the development of effective anticancer treatments.
全身治疗（如化疗和靶向治疗）对局部晚期、不可切除及转移性胆管癌（CCA）患者的疗效有限，总体生存期不足一年。肿瘤微环境（TME）代表肿瘤周围的生态系统，由免疫细胞、成纤维细胞、内皮细胞和多种可溶性因子组成。CCA的TME以丰富的促结缔组织增生性基质为特征，具有高度异质性，在癌症的发生和发展中起核心作用。越来越多的证据表明，将TME与其他治疗方式（如细胞毒性化疗或靶向治疗）联合作为靶点是可行的，这为可能产生协同效应的联合策略铺平了道路。在此，我们描述了CCA TME的组成部分，如癌症相关成纤维细胞和其他至关重要的细胞，以及它们最相关的相互作用，重点关注开发有效抗癌治疗方法的临床前理论依据。
